1921
Volume 97, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Afghanistan’s national guidelines recommend primaquine (PQ) for radical treatment of malaria, but this is rarely implemented because of concerns over potential hemolysis in patients who have G6PD deficiency. Between August 2009 and February 2014, we conducted an open-label, randomized controlled trial of chloroquine (CQ) alone versus chloroquine plus primaquine (0.25 mg base/kg/day for 14 days) (CQ+PQ) in patients aged 6 months and older with microscopy confirmed infection. In the CQ+PQ group, G6PD deficiency was excluded by fluorescent spot testing. The primary outcome was recurrence assessed by survival analysis over one year follow-up. Of 593 patients enrolled, 570 attended at or after 14 days of follow-up. recurrences occurred in 37 (13.1%) of 282 patients in the CQ+PQ arm versus 86 (29.9%) of 288 in the CQ arm (Cox proportional hazard ratio [HR] 0.37, 95% confidence interval [CI] 0.25–0.54) (intention-to-treat analysis). Protection against recurrence was greater in the first 6 months of follow-up (HR 0.082; 95% CI 0.029–0.23) than later (HR 0.65, 95% CI 0.41–1.03). Five of seven patients requiring hospital admission were considered possible cases of PQ-related hemolysis, and PQ was stopped in a further six; however, in none of these cases did hemoglobin fall by ≥ 2 g/dL or to below 7 g/dL, and genotyping did not detect any cases of Mediterranean variant G6PD deficiency. PQ 0.25 mg/kg/day for 14 days prevents relapse of in Afghanistan. Patient visits during the first week may improve adherence. Implementation will require deployment of point-of-care phenotypic tests for G6PD deficiency.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.17-0290
2017-12-06
2018-07-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/97/6/tpmd170290.html?itemId=/content/journals/10.4269/ajtmh.17-0290&mimeType=html&fmt=ahah

References

  1. Kolaczinski J, Graham K, Fahim A, Brooker S, Rowland M, , 2005. Malaria control in Afghanistan: progress and challenges. Lancet 365: 15061512.
  2. Leslie T, Nahzat S, Sediqi W, , 2016. Epidemiology and control of Plasmodium vivax in Afghanistan. Am J Trop Med Hyg 95: 7277.
  3. Garnham PC, , 1988. Swellengrebel lecture. Hypnozoites and ‘relapses’ in Plasmodium vivax and in vivax-like malaria. Trop Geogr Med 40: 187195.
  4. Leslie T, Rab MA, Ahmadzai H, Durrani N, Fayaz M, Kolaczinski J, Rowland M, , 2004. Compliance with 14-day primaquine therapy for radical cure of vivax malaria–a randomized placebo-controlled trial comparing unsupervised with supervised treatment. Trans R Soc Trop Med Hyg 98: 168173.
  5. Leslie T, Mayan I, Mohammed N, Erasmus P, Kolaczinski J, Whitty CJ, Rowland M, , 2008. A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan. PLoS One 3: e2861.
  6. Rowland M, Durrani N, , 1999. Randomized controlled trials of 5- and 14-days primaquine therapy against relapses of vivax malaria in an Afghan refugee settlement in Pakistan. Trans R Soc Trop Med Hyg 93: 641643.
  7. Bouma MJ, Goris M, Akhtar T, Khan N, Khan N, Kita E, , 1995. Prevalence and clinical presentation of glucose-6-phosphate dehydrogenase deficiency in Pakistani Pathan and Afghan refugee communities in Pakistan; implications for the use of primaquine in regional malaria control programmes. Trans R Soc Trop Med Hyg 89: 6264.
  8. Leslie T, Briceño M, Mayan I, Mohammed N, Klinkenberg E, Sibley CH, Whitty CJ, Rowland M, , 2010. The impact of phenotypic and genotypic G6PD deficiency on risk of Plasmodium vivax infection: a case-control study amongst Afghan refugees in Pakistan. PLoS Med 7: e1000283.
  9. Jamornthanyawat N, Awab GR, Tanomsing N, Pukrittayakamee S, Yamin F, Dondorp AM, Day NP, White NJ, Woodrow CJ, Imwong M, , 2014. A population survey of the glucose-6-phosphate dehydrogenase (G6PD) 563C>T (Mediterranean) mutation in Afghanistan. PLoS One 9: e88605.
  10. Faulde MK, Hoffmann R, Fazilat KM, Hoerauf A, , 2007. Malaria reemergence in northern Afghanistan. Emerg Infect Dis 13: 14021404.
  11. Dhir SL, Rahim A, , 1957. Malaria and its control in Afghanistan (1950–1954). Indian J Malariol 11: 73126.
  12. WHO, 2000. Severe and complicated malaria. Trans R Soc Trop Med Hyg 94 (Suppl 1): 190.
  13. Dell’edera D, 2012. Study of a family in the province of Matera presenting with glucose-6-phosphate dehydrogenase deficiency and Gilbert’s syndrome. Mol Med Rep 5: 15211525.
  14. Stepniewska K, White NJ, , 2006. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J 5: 127.
  15. Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, Looareesuwan S, White NJ, , 2000. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 44: 16801685.
  16. Awab GR, Imwong M, Pukrittayakamee S, Alim F, Hanpithakpong W, Tarning J, Dondorp AM, Day NP, White NJ, Woodrow CJ, , 2016. Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction. Malar J 15: 121.
  17. Snounou G, , 1996. Detection and identification of the four malaria parasite species infecting humans by PCR amplification. Methods Mol Biol 50: 263291.
  18. John GK, Douglas NM, von Seidlein L, Nosten F, Baird JK, White NJ, Price RN, , 2012. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J 11: 280.
  19. Kim JR, Nandy A, Maji AK, Addy M, Dondorp AM, Day NP, Pukrittayakamee S, White NJ, Imwong M, , 2012. Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata. PLoS One 7: e39645.
  20. Pukrittayakamee S, Vanijanonta S, Chantra A, Clemens R, White NJ, , 1994. Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J Infect Dis 169: 932935.
  21. Awab GR, Pukrittayakamee S, Imwong M, Dondorp AM, Woodrow CJ, Lee SJ, Day NP, Singhasivanon P, White NJ, Kaker F, , 2010. Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. Malar J 9: 105.
  22. Gogtay NJ, Desai S, Kamtekar KD, Kadam VS, Dalvi SS, Kshirsagar NA, , 1999. Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections. Ann Trop Med Parasitol 93: 809812.
  23. Rajgor DD, Gogtay NJ, Kadam VS, Kamtekar KD, Dalvi SS, Chogle AR, Aigal U, Bichile LS, Kain KC, Kshirsagar NA, , 2003. Efficacy of a 14-day primaquine regimen in preventing relapses in patients with Plasmodium vivax malaria in Mumbai, India. Trans R Soc Trop Med Hyg 97: 438440.
  24. Luxemburger C, van Vugt M, Jonathan S, McGready R, Looareesuwan S, White NJ, Nosten F, , 1999. Treatment of vivax malaria on the western border of Thailand. Trans R Soc Trop Med Hyg 93: 433438.
  25. Walsh DS, Wilairatana P, Tang DB, Heppner DG, Brewer TG, Krudsood S, Silachamroon U, Phumratanaprapin W, Siriyanonda D, Looareesuwan S, , 2004. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin Infect Dis 39: 10951103.
  26. Yeshiwondim AK, Tekle AH, Dengela DO, Yohannes AM, Teklehaimanot A, , 2010. Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia. Acta Trop 113: 105113.
  27. Llanos-Cuentas A, 2014. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 383: 10491058.
  28. Galappaththy GN, Omari AA, Tharyan P, , 2007. Primaquine for preventing relapses in people with Plasmodium vivax malaria. Cochrane Database Syst Rev CD004389.
  29. Galappaththy GN, Tharyan P, Kirubakaran R, , 2013. Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. Cochrane Database Syst Rev 10: CD004389.
  30. Pava Z, 2016. Submicroscopic and asymptomatic Plasmodium parasitaemia associated with significant risk of anaemia in Papua, Indonesia. PLoS One 11: e0165340.
  31. Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ, , 2014. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis 14: 982991.
  32. Improv Study Group, 2015. Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens. BMC Infect Dis 15: 558.
  33. Cheng Q, Cunningham J, Gatton ML, , 2015. Systematic review of sub-microscopic P. vivax infections: prevalence and determining factors. PLoS Negl Trop Dis 9: e3413.
  34. Tadesse FG, 2017. The shape of the iceberg: quantification of submicroscopic Plasmodium falciparum and Plasmodium vivax parasitaemia and gametocytaemia in five low endemic settings in Ethiopia. Malar J 16: 99.
  35. Leslie T, Mikhail A, Mayan I, Anwar M, Bakhtash S, Nader M, Chandler C, Whitty CJ, Rowland M, , 2012. Overdiagnosis and mistreatment of malaria among febrile patients at primary healthcare level in Afghanistan: observational study. BMJ 345: e4389.
  36. Kim S, 2011. Performance of the CareStart™ G6PD deficiency screening test, a point-of-care diagnostic for primaquine therapy screening. PLoS One 6: e28357.
  37. Bancone G, Chu CS, Chowwiwat N, Somsakchaicharoen R, Wilaisrisak P, Charunwatthana P, Bansil P, McGray S, Domingo GJ, Nosten FH, , 2015. Suitability of capillary blood for quantitative assessment of G6PD activity and performances of G6PD point-of-care tests. Am J Trop Med Hyg 92: 818824.
  38. Satyagraha AW, 2016. Assessment of point-of-care diagnostics for G6PD deficiency in malaria endemic rural eastern Indonesia. PLoS Negl Trop Dis 10: e0004457.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.17-0290
Loading
/content/journals/10.4269/ajtmh.17-0290
Loading

Data & Media loading...

  • Received : 08 Apr 2017
  • Accepted : 04 Aug 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error